166 related articles for article (PubMed ID: 27914687)
1. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
2. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
[TBL] [Abstract][Full Text] [Related]
3. Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter Status.
Millan-Esteban D; García-Casado Z; Macià A; de la Rosa I; Torrecilla-Vall-Llossera C; Penin RM; Manrique-Silva E; Pellegrini S; Biasin MR; Rizzolo P; Gavillero A; Di Stefani A; Pellegrini C; Requena C; Fargnoli MC; Peris K; Cota C; Menin C; Landi MT; Nagore E
Dermatology; 2024; 240(1):164-169. PubMed ID: 37918362
[TBL] [Abstract][Full Text] [Related]
4. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival.
Amit M; Tam S; Abdelmeguid AS; Roberts DB; Takahashi Y; Raza SM; Su SY; Kupferman ME; DeMonte F; Hanna EY
Br J Cancer; 2017 Jun; 116(12):1564-1571. PubMed ID: 28494469
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
[TBL] [Abstract][Full Text] [Related]
6. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
[TBL] [Abstract][Full Text] [Related]
7. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
[TBL] [Abstract][Full Text] [Related]
8. GNAQ mutation in a patient with metastatic mucosal melanoma.
Kim CY; Kim DW; Kim K; Curry J; Torres-Cabala C; Patel S
BMC Cancer; 2014 Jul; 14():516. PubMed ID: 25030020
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.
Neville G; Marzario B; Shilling D; Hand CK; Heffron C
Virchows Arch; 2024 Mar; 484(3):475-479. PubMed ID: 38183457
[TBL] [Abstract][Full Text] [Related]
10. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
Colombino M; Lissia A; Capone M; De Giorgi V; Massi D; Stanganelli I; Fonsatti E; Maio M; Botti G; Caracò C; Mozzillo N; Ascierto PA; Cossu A; Palmieri G
J Transl Med; 2013 Aug; 11():202. PubMed ID: 23987572
[TBL] [Abstract][Full Text] [Related]
12. BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.
Valentín-Bravo FJ; Pérez-Rodríguez Á; García-Álvarez C; García-Lagarto E; Saornil-Álvarez MA
Arq Bras Oftalmol; 2023; 86(5):e20230071. PubMed ID: 35544941
[TBL] [Abstract][Full Text] [Related]
13. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
[TBL] [Abstract][Full Text] [Related]
14. NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand.
Jones AM; Ferguson P; Gardner J; Rooker S; Sutton T; Ahn A; Chatterjee A; Bickley VM; Sarwar M; Emanuel P; Kenwright D; Shepherd PR; Eccles MR
Oncotarget; 2016 Jul; 7(27):41017-41030. PubMed ID: 27191502
[TBL] [Abstract][Full Text] [Related]
15. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.
Newell F; Wilmott JS; Johansson PA; Nones K; Addala V; Mukhopadhyay P; Broit N; Amato CM; Van Gulick R; Kazakoff SH; Patch AM; Koufariotis LT; Lakis V; Leonard C; Wood S; Holmes O; Xu Q; Lewis K; Medina T; Gonzalez R; Saw RPM; Spillane AJ; Stretch JR; Rawson RV; Ferguson PM; Dodds TJ; Thompson JF; Long GV; Levesque MP; Robinson WA; Pearson JV; Mann GJ; Scolyer RA; Waddell N; Hayward NK
Nat Commun; 2020 Oct; 11(1):5259. PubMed ID: 33067454
[TBL] [Abstract][Full Text] [Related]
16. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Undifferentiated Melanoma Mimicking a Primary Bone Tumor: A Potential Diagnostic Pitfall.
Wills A; Dibbern M; Frierson HF; Raghavan SS
Am J Dermatopathol; 2024 Mar; 46(3):170-172. PubMed ID: 38170737
[TBL] [Abstract][Full Text] [Related]
18. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.
Murphy BM; Terrell EM; Chirasani VR; Weiss TJ; Lew RE; Holderbaum AM; Dhakal A; Posada V; Fort M; Bodnar MS; Carey LM; Chen M; Burd CJ; Coppola V; Morrison DK; Campbell SL; Burd CE
Nat Commun; 2022 Jun; 13(1):3153. PubMed ID: 35672316
[TBL] [Abstract][Full Text] [Related]
19. The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
Geiger CE; Mrabet-Dahbi S; Berger I
Melanoma Res; 2024 Feb; 34(1):85-87. PubMed ID: 38127894
[No Abstract] [Full Text] [Related]
20. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
